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Tumor-bone cell interactions are critical for the development of metastasis-related osteolytic bone destruc-
tion. In this issue ofCancer Cell, Ell and colleagues show how a discretemiRNA network regulates osteoclas-
togenesis during breast cancer bone metastasis. A signature of upregulated miRNAs may have diagnostic
and therapeutic implications for bone metastases.Advanced breast cancer commonly
metastasizes to bone, where it causes os-
teolytic bone destruction and associated
bone pain and fracture, hypercalcemia,
and paralysis due to spinal cord compres-
sion. In thebonemicroenvironment, tumor
cells hijack the bone remodeling process,
normally orchestrated by osteoclasts, os-
teoblasts, andosteocytes, towreak havoc
and weaken the bone. Osteoclast differ-
entiation and bone resorption is depen-
dent on macrophage colony-stimulating
factor and receptor activator of NF-kB
ligand (RANKL) (Boyle et al., 2003). Once
in the bone, breast cancer cells release
factors that send osteoclasts into over-
drive by recruiting preosteoclasts and
inducing their differentiation. Osteoclastic
bone resorption releases growth factors
stored in the bone, such as transforming
growth factor b (TGF-b), which in turn
drives tumor cell production of factors
that further increase osteoclast activity
(Weilbaecher et al., 2011). This feed-forward vicious cycle creates a fertile
microenvironment for tumor growth in
bone to drive the devastating effects of
bone destruction and render the tumor
incurable.
Therapy for patients with bone metas-
tases attacks the tumor cells as well
as the bone microenvironment. Antire-
sorptive therapy, bisphosphonates (zole-
dronic acid), and the RANKL antibody
(denosumab) are standard-of-care to
target osteoclast hyperactivity. These
drugs effectively reduce skeletal-related
events due to bone metastases but do
not cure disease. Further, it is difficult to
predict whowill develop bonemetastases
due to lack of broadly applicable bio-
markers to better guide long term preven-
tive therapy.
In this issue of Cancer Cell, Ell et al.
(2013) propose a single approach to treat
and predict bone metastases based
on microRNA (miRNA). Specifically, they
identify a miRNA signature induced byhighly metastatic tumor cells that stimu-
lates differentiation of osteoclasts and
recruits preosteoclasts to the site of the
tumor-bone interface (Figure 1). miRNAs
repress gene expression through comple-
mentary binding to the ‘‘seed sequence’’
of mRNAs (Bartel, 2009) and are impor-
tant for osteoclastogenesis (Mizoguchi
et al., 2010; Sugatani and Hruska, 2007;
Zhang et al., 2012). Here, the authors
demonstrate how breast cancer cell inva-
sion in the bone co-opts this normal pro-
cess to hyperactivate osteoclasts and
prime the bone for osteolytic destruction.
This represents significant insight into our
understanding of the organ-specific func-
tion and pathological activity of miRNAs,
which could lead to improvements in
diagnosis, treatment, and prevention of
bone metastases and elucidates a unique
aspect of the bone microenvironment to
support tumor growth in bone.
To identify miRNAs modulated during
osteoclastogenesis, the authors used, October 14, 2013 ª2013 Elsevier Inc. 407
Figure 1. Feed-Forward Vicious Cycle of Bone Metastases Involves sICAM1 and miRNAs
Highly metastatic tumor cells infiltrating the bone microenvironment from the vasculature, secrete soluble
forms of ICAM1 (sICAM1, orange balls), which stimulate a distinct miRNA expression signature in osteo-
clasts to fuel osteoclastogenesis and bone destruction, are shown. miRNA expression correlates with
expression of sICAM1 from tumor cells. This increased bone resorption releases TGF-b from the bone
matrix. In this setting, TGF-b could potentially act on tumor cells to further increase ICAM1 expression
as well as miRNAs that influence epithelial-mesenchymal transition (EMT). sICAM1 may play a significant
role in both of these pathways. sICAM1 indirectly influences bone resorption, as demonstrated in Ell et al.
(2013). In addition, ICAM1 expressed on osteoblasts acts as a ligand for lymphocyte function-associated
antigen-1 (LFA-1) on preosteoclasts (Pre-OC) to stimulate osteoclastogenesis. sICAM1 secreted by
tumors may also act in an autocrine fashion on cancer cells. sICAM1 can facilitate tumor adhesion, migra-
tion and extravasation by interaction with factors known to influence tumor invasion, such as CXCR4,
TNFa, SDF-1, and MMP-2.
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Previewsconditioned media (CM) from tumor cells
(breast and bladder cancer) with highmet-
astatic potential with or without RANKL
to compare miRNA expression changes
in RAW264.7 osteoclast precursor cells.
Forty two upregulated and 45 down-
regulated miRNAs (>2.2-fold change)
were identified across treatment groups.
Five miRNAs that were significantly
downregulated during osteoclastogene-
sis in both physiological and pathophys-
iological conditions (miR-33a, miR-133,
miR-141, miR-190, and miR-219) were
further analyzed. Ectopic expression of
miR133a, miR-141, and miR-219 strongly
inhibitedosteoclastogenesis. Theeffect of
this miRNA signature on osteoclast activ-
ity was validated by the examination of
genes known to be important for osteo-
clast differentiation (Mitf, Calcr, Traf6,
andMmp14).408 Cancer Cell 24, October 14, 2013 ª2013Remarkably, miR-141 and miR-219
administered systemically led to a signifi-
cant decrease in the number of osteo-
clasts in vivo, and these same miRNAs
reduced metastatic tumor burden in an
experimental breast cancer (MDA-MB-
231) bone metastasis model. The thera-
peutic effect of systemic miRNA treat-
ment in mice with MDA-MB-231 bone
metastases was as effective to reduce
bone metastases as the standard-of-
care, zoledronic acid.
A signature of upregulated miRNAs
(miR-16, miR-211, miR-378, and Let-7a)
during osteoclast differentiation was
also determined. Because these did not
significantly impact osteoclastogenesis,
the authors thought to investigate this
signature as a useful biomarker for os-
teolytic bone metastasis. miR-16 and
miR-378 were consistently increased inElsevier Inc.serum from mice with highly metastatic
breast cancer cells and in serum from
patients with breast cancer metastatic
to bone as compared to healthy female
donors.
Osteoclastogenesis induced by tumor
cell CM showed a similar set of miRNA
changes as RANKL treatment and led
the authors to determine what factor(s)
in CM could induce osteoclast activity.
Cytokine expression analysis of CM re-
vealed that soluble ICAM1 (sICAM1) was
released from highly metastatic tumor
cells and enhanced osteoclast activation.
In addition, sICAM1 enhanced migration
of preosteoclasts in vitro, suggesting it
may also play a role in the recruitment of
preosteoclasts to the site of bone resorp-
tion, though this is yet to be confirmed
in vivo. It has also been reported that
expression of ICAM1 on osteoblasts
could directly bind lymphocyte function-
associated antigen-1 (LFA-1) on preos-
teoclasts to drive osteoclastogenesis
(Figure 1) (Tanaka et al., 2000). Neutral-
izing antibody to ICAM1 has also been
shown to reduce osteoclast formation
via this mechanism. ICAM could also be
involved in the recruitment of tumor cells
to the site of bone metastasis directly,
as it is known to increase migration and
adhesion of MDA-MB-231 cells under in-
flammatory conditions (Evani et al., 2013).
To investigate the clinical significance
of sICAM1 as a tumor-derived factor
involved in osteoclastogenesis, the au-
thors measured serum sICAM1 concen-
trations from healthy donors and patients
with either primary (local) breast cancer
or breast cancer with bone metasta-
ses. Serum sICAM1 concentrations were
significantly increased in patients with
bone metastases and correlated with an
increase in miR-16 and miR-378. In addi-
tion, miR-16 exhibited higher specificity
than N-terminal telopeptide, the standard
marker of bone turnover, in serum sam-
ples from patients with bone metastases
relative to patients without bone metasta-
ses or healthy donors.
This study elegantly shows that a
miRNA regulatory network is strongly
involved in both physiological and patho-
logical bone remodeling. This is the best
description yet of an organ-specific role
of miRNA regulation and how dysregula-
tion of miRNAs during bone metasta-
sis correlates with metastatic capacity.
These findings also raise important
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Previewsquestions (Figure 1). First, could the miR-
NAs identified in this study inhibit tumor
cells directly? The authors state that these
miRNAs do not have any effect on the
growth or survival of tumor cells in vitro,
but the in vivo possibility remains. Sec-
ond, does expression of sICAM1 from
tumor cells at a distant site prime them
to metastasize to bone or do tumor
cells require cues from the bone-tumor
microenvironment to elicit an increase
in ICAM1? Finally, because TGF-b is
released in large amounts during cancer-
induced bone destruction, could TGF-b
directly regulate miRNAs? For example,
it can induce miRNAs in MDA-MB-231
breast cancer, which increases metasta-
tic potential and epithelial-mesenchymal
transition (EMT) (Taylor et al., 2013), but
it also represses miRNAs that result in
the same effect (Ding et al., 2013).
Use of the technology described in this
study to identify and validate miRNAs as
diagnostic and therapeutic tools is power-
ful. Could these miRNAs identify patients
at higher risk for bone metastasis? Could
miRNA therapy be as effective as current
antiresorptive therapy? The studies in
mice predict that the miRNAs will be as
effective as zoledronic acid in humans,but it will be important to compare to
denosumab, which is about 20% more
effective to reduce skeletal-related events
in head-to-head trials with zoledronic
acid. Will miRNA antiresorptive therapy
be associated with potential adverse
events such as osteonecrosis of the jaw
or atypical fractures? Do the miRNAs
have effects on osteoblasts and osteo-
cytes? Are miRNAs dysregulated in other
diseases also associated with increased
osteoclast activity such as osteoporosis,
Paget’s disease, or fibrous dysplasia?
Answers to these important questions
will shed new light into the pathophysi-
ology of bone metastases, the tumor
microenvironment, as well as regulation
of osteoclastogenesis and have important
implications for the diagnosis, prognosis,
and treatment of this devastating compli-
cation of malignancy.ACKNOWLEDGMENTS
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